Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Meng WuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.ORCID https://orcid.org/0000-0003-3479-2547
Caixia LiNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID https://orcid.org/0000-0002-5480-3023
Zengjun LiDepartment of Hematology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.ORCID https://orcid.org/0009-0003-7697-5971
Jian ZhouDepartment of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.ORCID https://orcid.org/0000-0001-8290-3104
Xiaopei WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.ORCID https://orcid.org/0009-0001-7689-3138
Yuqin SongKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.ORCID https://orcid.org/0000-0001-5451-6481
Jun ZhuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Hui LiuDepartment of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.ORCID https://orcid.org/0000-0002-8166-0216
Weiping LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.ORCID https://orcid.org/0000-0002-0367-1411
Funding
Beijing Municipal Natural Science Foundation L244025Beijing Municipal Natural Science Foundation L244063Beijing Research Ward Excellence Program BRWEP2024032150207Beijing Research Ward Excellence Program BRWEP2024W032150205Beijing Research Ward Excellence Program BRWEP2024W032150206Beijing Research Ward Excellence Program BRWEP2024W032150208Beijing Research Ward Excellence Program BRWEP2024W032150213Capital's Funds for Health Improvement and Research 2022-1-2152Capital's Funds for Health Improvement and Research 2024-1-2151National Natural Science Foundation of China 32300655National Natural Science Foundation of China 82270195Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0500800
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study. · full record | OpenQuestion